BETA
Your AI-Trained Oncology Knowledge Connection!
Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer
"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.
2025 ASCO Annual Meeting: The Show and After Show
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma
Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.
Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
Kit Yu Lu, MD, identifies patients with HR+/HER2– metastatic breast cancer who may benefit from earlier T-DXd or sacituzumab govitecan treatment.
FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data
The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.
Perioperative Nivolumab Combo Earns EU Approval in PD-L1+ Resectable NSCLC
Findings from the CheckMate 77T study support the approval of this nivolumab-based regimen in the European Union.
ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC
Creating an Accommodating Pediatric Cancer Care Experience
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
3 Things You Should Know About Advances in CLL Management
Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.
Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma
Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer
Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.
Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC
For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.
Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC
The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
3 Things You Should Know About the Multimodal Treatment of SCLC
Here are 3 things you should know about the multimodal treatment of patients with SCLC.
Leveraging Artificial Intelligence to Bolster Equitable Cancer Care
Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
Fostering Multidisciplinary Collaboration in Brain Tumor Management
Jennifer Moliterno, MD, FAANS, discusses effective collaboration strategies with multidisciplinary colleagues to optimize treatment for brain tumors.
Combined VEGF/PD-L1 Inhibition Displays Frontline Efficacy in ES-SCLC
No new safety signals were observed with bevacizumab, atezolizumab, carboplatin, and etoposide in extensive-stage small cell lung cancer.
Differentiating Bispecific Administration Between Institutions for Multiple Myeloma
A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?
Disitamab Vedotin Combo Extends PFS/OS in HER2+ Urothelial Carcinoma
Treatment with disitamab vedotin and toripalimab improves survival regardless of cisplatin eligibility or HER2 expression level in the phase 3 RC48-C016 trial.
Daratumumab Combo Prolonged Efficacy in Asian Patients with Multiple Myeloma
The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.
Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL
CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.
ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer
Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations
Avutometinib/Defactinib Appears Tolerable in KRAS-Mutant LGSOC
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma
CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.
FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma
The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.
